Should I buy or sell Exagen stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares. View XGN analyst ratings or view top-rated stocks .

What is Exagen's stock price target for 2024?

3 brokers have issued 1-year price targets for Exagen's shares. Their XGN share price targets range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 200.5% from the stock's current price. View analysts price targets for XGN or view top-rated stocks among Wall Street analysts .

How have XGN shares performed in 2023?

Exagen's stock was trading at $2.40 at the start of the year. Since then, XGN stock has decreased by 23.8% and is now trading at $1.83. View the best growth stocks for 2023 here .

When is Exagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024. View our XGN earnings forecast .

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) announced its earnings results on Wednesday, November, 10th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.04. The company earned $12.25 million during the quarter, compared to analysts' expectations of $12.13 million. Exagen had a negative trailing twelve-month return on equity of 81.62% and a negative net margin of 62.90%. During the same period in the prior year, the company earned ($0.34) EPS.

What guidance has Exagen issued on next quarter's earnings?

Exagen issued an update on its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $50.00M-, compared to the consensus revenue estimate of $46.76 million.

What is Ron Rocca's approval rating as Exagen's CEO?

5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com . Ron Rocca has an approval rating of 80% among the company's employees.

(XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

Who are Exagen's major shareholders?

Exagen's stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (7.14%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Hunt Holdings Limited Partners, James L L Tullis , John Aballi, Mark Hazeltine, Nmsic Co-Investment Fund, LP and Wendy S Johnson . View institutional ownership trends .

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Exagen Stock Price, News & Analysis (NASDAQ:XGN)

$1.86

+0.05 (+2.76%)

(As of 01:37 PM ET)

Compare

Today's Range: $1.79
▼
$1.93
50-Day Range: $1.45
▼
$2.53
52-Week Range: $1.33
▼
$3.92

Volume: 11,255 shs
Average Volume: 20,478 shs
Market Capitalization: $31.71 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Exagen MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 200.5% Upside
$5.50 Price Target
Short Interest: Healthy
0.09% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.29
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$59,183 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.46) to ($1.41) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

79th out of 949 stocks

Medical Laboratories Industry

2nd out of 21 stocks

3.5

Analyst's Opinion

Consensus Rating
Exagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, Exagen has a forecasted upside of 200.5% from its current price of $1.83.
Amount of Analyst Coverage
Exagen has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.09% of the float of Exagen has been sold short.
Short Interest Ratio / Days to Cover
Exagen has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Exagen has recently increased by 4.17%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Exagen does not currently pay a dividend.
Dividend Growth
Exagen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exagen has received a 70.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Immunology laboratory services for research" products. See details.
Environmental Sustainability
The Environmental Impact score for Exagen is -1.29.

0.6

News and Social Media Coverage

Search Interest
2 people have searched for XGN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exagen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $59,183.00 in company stock.
Percentage Held by Insiders
36.80% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
40.85% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Exagen are expected to grow in the coming year, from ($1.46) to ($1.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exagen is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exagen is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Exagen has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Exagen Stock (NASDAQ:XGN)

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

XGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XGN Stock News Headlines

November 17, 2023 | msn.com

Exagen files for a $150M mixed shelf offering

November 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Exagen (XGN) and Milestone Pharmaceuticals (MIST)

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 13, 2023 | msn.com

Exagen GAAP EPS of -$0.31 beats by $0.15, revenue of $13.4M beats by $3.07M

November 13, 2023 | finance.yahoo.com

Exagen Inc. Reports Strong Third Quarter 2023 Results

November 12, 2023 | markets.businessinsider.com

Here's what to expect from Exagen's earnings report

November 10, 2023 | benzinga.com

Earnings Preview For Exagen

November 9, 2023 | msn.com

Exagen licenses lupus nephritis biomarkers from Johns Hopkins

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 9, 2023 | finance.yahoo.com

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

November 2, 2023 | finance.yahoo.com

Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

November 1, 2023 | morningstar.com

Exagen Inc Ordinary Shares XGN

October 30, 2023 | finance.yahoo.com

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

September 28, 2023 | finance.yahoo.com

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

September 12, 2023 | finance.yahoo.com

Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

August 9, 2023 | finance.yahoo.com

Exagen Inc. (NASDAQ:XGN) Q2 2023 Earnings Call Transcript

August 7, 2023 | msn.com

Exagen beats Q2 top and bottom line estimates; initiates Q3 outlook

August 7, 2023 | finance.yahoo.com

Exagen Inc. Reports Strong Second Quarter 2023 Results

August 4, 2023 | benzinga.com

Exagen's Earnings Outlook

July 26, 2023 | finance.yahoo.com

Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference

July 25, 2023 | finance.yahoo.com

Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023

July 24, 2023 | finance.yahoo.com

Exagen Inc. Appoints Paul Kim to Board of Directors

July 24, 2023 | finance.yahoo.com

This Exagen Insider Increased Their Holding In The Last Year

June 13, 2023 | finance.yahoo.com

Exagen Inc.'s (NASDAQ:XGN) Low P/S No Reason For Excitement

May 30, 2023 | finance.yahoo.com

Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference

May 17, 2023 | finance.yahoo.com

Exagen (NASDAQ:XGN) shareholders are up 20% this past week, but still in the red over the last three years

May 16, 2023 | msn.com

Cantor Fitzgerald Reiterates Exagen (XGN) Overweight Recommendation

See More Headlines

Receive XGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XGN
CUSIP: N/A
CIK: 1274737
Web: www.exagen.com
Phone: 760-560-1501
Fax: N/A
Employees: 199
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.50
High Stock Price Target: $6.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +200.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,390,000.00
Net Margins: -62.90%
Pretax Margin: -63.45%
Return on Equity: -81.62%
Return on Assets: -38.71%

Debt

Debt-to-Equity Ratio: 0.70
Current Ratio: 4.83
Quick Ratio: 4.83

Sales & Book Value

Annual Sales: $45.56 million
Price / Sales: 0.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.61 per share
Price / Book: 0.70

Miscellaneous

Outstanding Shares: 17,050,000
Free Float: 10,773,000
Market Cap: $31.20 million
Optionable: Not Optionable
Beta: 1.21

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Tina S. Nova Ph.D. (Age 69)
Executive Chairman of Board
Comp: $65k
Mr. John Aballi (Age 38)
CEO, President & Director
Comp: $558.84k
Mr. Kamal Adawi M.S. (Age 44)
MBA, CFO & Corporate Secretary
Comp: $483.28k
Mr. Mark Hazeltine (Age 49)
Chief Business Officer
Comp: $483.28k
Ryan Douglas
Investors Relations Officer
Mr. John Wegener (Age 54)
Senior Vice President of Sales and Marketing
Dr. Andrew L. Concoff FACR
M.D., Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
Dr. Michael I. Nerenberg M.D. (Age 68)
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Exagen stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exagen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XGN shares.
View XGN analyst ratings or view top-rated stocks.
What is Exagen's stock price target for 2024?: 3 brokers have issued 1-year price targets for Exagen's shares. Their XGN share price targets range from $5.00 to $6.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 200.5% from the stock's current price.
View analysts price targets for XGN or view top-rated stocks among Wall Street analysts.
How have XGN shares performed in 2023?: Exagen's stock was trading at $2.40 at the start of the year. Since then, XGN stock has decreased by 23.8% and is now trading at $1.83.
View the best growth stocks for 2023 here.
When is Exagen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024.
View our XGN earnings forecast.
How were Exagen's earnings last quarter?: Exagen Inc. (NASDAQ:XGN) announced its earnings results on Wednesday, November, 10th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.04. The company earned $12.25 million during the quarter, compared to analysts' expectations of $12.13 million. Exagen had a negative trailing twelve-month return on equity of 81.62% and a negative net margin of 62.90%. During the same period in the prior year, the company earned ($0.34) EPS.
What guidance has Exagen issued on next quarter's earnings?: Exagen issued an update on its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $50.00M-, compared to the consensus revenue estimate of $46.76 million.

What is Ron Rocca's approval rating as Exagen's CEO?: 5 employees have rated Exagen Chief Executive Officer Ron Rocca on Glassdoor.com. Ron Rocca has an approval rating of 80% among the company's employees.
When did Exagen IPO?: (XGN) raised $50 million in an IPO on Thursday, September 19th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.
Who are Exagen's major shareholders?: Exagen's stock is owned by many different institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (7.14%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Hunt Holdings Limited Partners, James L L Tullis, John Aballi, Mark Hazeltine, Nmsic Co-Investment Fund, LP and Wendy S Johnson.
View institutional ownership trends.
How do I buy shares of Exagen?: Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:XGN) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial